ACM
CERE

ADAR1 Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

ADAR1 Capital Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-93,350
Closed -$3.82M – 361
2024
Q2 		$3.82M Buy
93,350
+69,091
+285% +$2.88M 0.72% 26
2024
Q1 		$1.03M Sell
24,259
-86,441
-78% -$3.63M 0.23% 61
2023
Q4 		$4.69M Buy
+110,700
New +$3.18M 1.68% 15

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

ADAR1 Capital Management's CERE Position: Q3 2024 in Review

ADAR1 Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 93,350 shares — an estimated $3.82M sold.

ADAR1 Capital Management first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $4.69M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • ADAR1 Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • ADAR1 Capital Management sold 93,350 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $3.82M.
  • ADAR1 Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
  • ADAR1 Capital Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $4.69M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on ADAR1 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.